Zoledronic Acid reduces clinically significant fractures in mHSPC
April 28th 2023A database analysis of patients who participated in the STAMPEDE trial showed that zoledronic acid can significantly lower the risk of fracture in patients with with metastatic hormone-sensitive prostate cancer starting long-term ADT.
Study shows feasibility of PSMA-directed fluorescence imaging during radical prostatectomy
April 18th 2023The PSMA-targeted fluorescent tracer OTL78 was shown to be safe and enabled real-time imaging during robot-assisted radical prostatectomy and provided valuable information on the localization and extent of prostate cancer.
Dr. Grivas discusses real-world study of frontline avelumab maintenance in urothelial carcinoma
March 10th 2023Avelumab is approved by the FDA as a maintenance therapy for patients with locally advanced/metastatic urothelial carcinoma that has not progressed with first-line, platinum-based chemotherapy.
Plant-based diets linked to lower risk of prostate cancer progression and recurrence
March 7th 2023"These findings may directly inform clinical care, such as providing diet recommendations for managing health, and potentially offer other positive health benefits for preventing numerous chronic diseases,” said Bradley Alexander McGregor, MD.
Gene therapy EG-70 shows early promise in BCG-unresponsive NMIBC
February 27th 2023"While the data are still early, EG-70's safety profile and efficacy are well on their way towards establishing a new benchmark for monotherapy treatment of high-risk NMIBC with BCG-unresponsive carcinoma in situ,” said lead study author Gary Steinberg MD.
Trial of 64Cu SAR-bisPSMA in biochemically recurrent prostate cancer hits enrollment goal
February 9th 2023"We are very pleased to have reached our recruitment target for the COBRA trial. The data generated thus far on the SAR-bisPSMA product is very encouraging and shows high uptake of the agent by prostate cancer cells,” said Neal Shore, MD.